(19)
(11) EP 4 419 094 A1

(12)

(43) Date of publication:
28.08.2024 Bulletin 2024/35

(21) Application number: 22884534.3

(22) Date of filing: 21.10.2022
(51) International Patent Classification (IPC): 
A61K 31/18(2006.01)
C12Q 1/68(2018.01)
 A61P 35/00(2006.01)
G01N 33/50(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61K 45/06; A61K 31/165
(86) International application number:
PCT/US2022/047447
(87) International publication number:
WO 2023/069727 (27.04.2023 Gazette 2023/17)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 21.10.2021 US 202163270382 P

(71) Applicant: Edison Oncology
Menlo Park, CA 94025 (US)

(72) Inventors:
  • BACHA, Jeffrey A.
    Menlo Park, CA 94025 (US)
  • BROWN, Dennis
    Menlo Park, CA 94025 (US)

(74) Representative: Forresters IP LLP 
Skygarden Erika-Mann-Straße 11
80636 München
80636 München (DE)

   


(54) COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS